IndexBox projects a 9.4% compound annual growth rate for the global non-insulin peptide drugs market through 2035, with GLP-1 demand driving volume. The report names GMP-grade synthesis capacity, not raw materials, as the sector's binding constraint.
A GlobeNewswire release says a review of supplier Kylo Peptides sets a documentation benchmark for the research peptide market, citing lot-matched COAs and four independent testing labs. It also cites a 2026 analysis in which fewer than six in ten sampled research peptides met both purity and label-accuracy thresholds.
The Precision Peptide Company has ordered 20,000 units of a 2 mg Thymosin Alpha-1 transdermal patch, its first commercial run of the product. The clinical review it cites covers subcutaneous injection, not the patch, which the company says is still in testing.
NextWave Peptides says it is restructuring its catalog so product information and lot specific Certificates of Analysis stay connected but distinct, and states a 99%+ purity standard with third party testing. Every figure in the announcement comes from the company itself, and no testing laboratory is named.
Nox Peptides has launched GHK-Cu and a combination product containing BPC-157 and TB-500 for Canadian research buyers, the company said in an October 6 announcement. No trial, outcome figure or published study accompanies the launch, and the release makes no health claims.
Canadian supplier Nox Peptides has announced an expanded focus on research peptides including BPC-157, in a press release carrying no study, no figure and no named researcher. The company says its products are for laboratory use only and not for human consumption.
Greenwich Rx, a 503A compounding pharmacy in Texas, is voluntarily recalling lots of compounded glutathione nationwide over potential elevated endotoxin levels. The company says two patients received emergency department care after intravenous administration of a glutathione product not formulated for IV use.
NAD+ is sold as both a clinic infusion and an oral precursor, but none of the current coverage names a human trial, a dose or an outcome figure. A New York medical examiner has ruled one infusion death a homicide, while dermatologists are still publicly asking whether the category is hope or hype.
An FDA advisory committee voted in July to recommend MOTS-c for the 503A Bulks List, but the vote carries no legal effect and the rulemaking has not started. None of the available coverage names a single human trial of the mitochondrial-derived peptide, its size or its result.
Umbrella Labs says it has standardized naming, identity fields, and batch traceability for its MOTS-C research material, with no biological claims attached. The announcement is a procurement story rather than a science one, and the company says the material's research-use-only scope is unchanged.
A Nerdbot review scores research-peptide supplier Cellugenix 9.5 out of 10, citing a public batch certificate library, 99%+ documented purity, and testing through a named independent lab. Every figure in it comes from the company's own site and documentation, and no samples were independently assayed for the review.
Centric Compounding is recalling six lots of Glutathione, Myer's Cocktail, and Tri-Immune Boost injectable vials nationwide after elevated endotoxin levels were found in the glutathione ingredient. The company says it has already received nine reports of fever, chills, chest pain, and other symptoms.
Australia's TGA has warned about counterfeit peptide products after a patient tore their oesophagus from severe vomiting following use of a product sold as retatrutide. Testing found no retatrutide in the sample, but semaglutide at roughly eight times the level in approved products.
A preprint curating U.S. clinical notes found BPC-157 use rose 33-fold between 2020 and 2026, with pain and gastrointestinal conditions the most documented reasons. The authors say the records cannot establish efficacy, and the peptide's compounding status remains unresolved.
Bowery Clinic says it has expanded its physician-guided Selank program and published an educational overview of the synthetic peptide. The human trials it cites involve about 60 patients each, and Selank is not FDA-approved for anything in the United States.
Retatrutide has not been approved and has no legal commercial supply, yet import reviewers logged eight shipments in two months, one declaring 222,930 pieces. Here is what the public record on the compound actually contains, and what it does not.
Us Weekly's affiliate shopping feature recommends Londontown's Peptide Serum Concentrate for brittle nails, crediting a blend of cranberry peptides, aloe, glycerin and panthenol. No trial, figure or clinician appears anywhere in the piece, and the only support offered is a single customer review.
Synthesis Peptides says it now pulls eight vials at random from every production lot for HPLC and LC-MS testing, with batch-specific Certificates of Analysis published publicly. The release names no purity threshold and does not identify the independent testing lab.
A Partnership for Safe Medicines review of May and June 2026 import data found eight retatrutide shipments, one declaring 222,930 pieces, for a drug still in clinical trials. It also found 23% of peptide shipments came from facilities identified as illegitimate manufacturers while only 4% were refused entry.
A ten-vendor audit scored peptide suppliers on certificates, named labs, lot matching and price per milligram, and found the expensive end of the market is not the documented end.
Doctors in Victoria told the ABC they suspect a contaminated batch of counterfeit peptides is behind seven hospitalizations for acute liver toxicity. The TGA says the retatrutide sold online is not the product Eli Lilly is testing in trials.
